利拉鲁肽联合二甲双胍治疗2型糖尿病伴肥胖患者疗效及对微炎症状态的影响  

Effect of liraglutide combined with metformin on type 2 diabetes patients with obesity and its impact on micro-inflammatory state

作　　者：赵富利[1] 亓民[1] 刘辉[2] 

机构地区：[1]郑州大学附属洛阳中心医院老年病科,河南洛阳471000 [2]郑州大学附属洛阳中心医院内分泌科,河南洛阳471000

出　　处：《中国现代医学杂志》2015年第15期43-46,共4页China Journal of Modern Medicine

摘　　要：目的分析利拉鲁肽联合二甲双胍治疗2型糖尿病伴肥胖患者疗效及对患者微炎症状态的影响。方法选择2013年1月-2014年1月期间郑州大学附属洛阳中心医院收治的2型糖尿病伴肥胖患者88例作为研究对象,按照随机数表法将所有入组患者分为对照组和观察组,各44例。对照组患者接受单纯二甲双胍治疗,观察组患者接受利拉鲁肽联合二甲双胍治疗。比较两组患者的体质指数、血糖水平、微炎症水平及脂质水平等差异。结果观察组患者接受治疗后的BMI、FBG、Hb A1c水平均明显低于对照组患者(P<0.05)。观察组患者接受治疗后的ASAA、TNF-α、IL-6水平均明显低于对照组患者(P<0.05)。观察组患者接受治疗后的TG、LDL-C水平低于对照组患者,HDL-C水平高于对照组患者(P<0.05)。结论利拉鲁肽联合二甲双胍治疗可以降低2型糖尿病伴肥胖患者的体质指数及血糖水平,优化全身炎症状态及脂质水平。[ Objective ] To analyze the effect of liraglutide combined with metformin on type 2 diabetes with obe- sity and its impact on patients＂ micro-inflammatory state. [Methods] A total of 88 cases of type 2 diabetes patients with obesity in our hospital were chosen as research subjects, according to random indicator method divided into control group and observation group with 44 eases in each group. The patients in the control group were treated with mefformin alone, and the patients in the observation group received liraglutide combined with mefformin. The body mass index （BMI）, the levels of blood sugar （FBG and HbAlc）, micro-inflammation and blood lipids in the two groups were compared. [Results] The BMI, FBG and HbAle levels in the observation group were significantly lower than those in the control group （P 〈 0.05）. The ASAA, TNF-α and IL-6 levels in the observation group were signifi- cantly lower than those in the control group （P 〈 0.05）. The TG and LDL-C levels in the observation group were lower than those in the control group, while HDL-C level was higher （P 〈 0.05）. [ Conclusions ] Liraglutide com- bined with mefformin therapy could reduce the BMI and blood sugar levels in type 2 diabetes patients with obesity, and improve state of systemic inflammation and lipid levels.

关 键 词：2型糖尿病伴肥胖 利拉鲁肽 二甲双胍 

分 类 号：R587.1[医药卫生—内分泌]